Liposomes Patents (Class 424/450)
-
Patent number: 10894956Abstract: Described herein are phospholipid nanogels that can contain a low concentration (less than about 250 ?Units/?L) of an exoglycosidase enzyme. Also described herein are systems and devices that can contain a phospholipid nanogel that can contain a low concentration (less than about 250 ?Units/?L) of an exoglycosidase enzyme. Also described herein are methods of using the phospholipid nanogels described herein and devices and systems that can contain a phospholipid nanogel described herein.Type: GrantFiled: March 5, 2018Date of Patent: January 19, 2021Assignee: West Virginia UniversityInventors: Lisa Holland, Srikanth Gattu
-
Patent number: 10888622Abstract: A nanocomplex containing a delivery agent and a pharmaceutical agent. The nanocomplex has a particle size of 50 to 1000 nm, the delivery agent binds to the pharmaceutical agent via non-covalent interaction or covalent bonding, and the pharmaceutical agent is a modified peptide or protein formed of a peptide or protein and an added chemical moiety that contains an anionic group, a disulfide group, a hydrophobic group, a pH responsive group, a light responsive group, a reactive oxygen species responsive group, or a combination thereof.Type: GrantFiled: May 13, 2014Date of Patent: January 12, 2021Assignee: Trustees of Tufts CollegeInventors: Qiaobing Xu, Ming Wang
-
Patent number: 10888572Abstract: A hydrated lecithin carrier vesicle composition includes lecithin and a triglyceride source or fatty acid in conditioned water. The disclosed compositions may be used for controlling appetite, weight loss, modulating effects from alcohol consumption, and/or delivering active agents to the small intestine.Type: GrantFiled: December 2, 2016Date of Patent: January 12, 2021Assignee: BIO-UP MIMETIC TECHNOLOGIES, INC.Inventors: Donald F. Hodgson, Crispin G. S. Eley
-
Patent number: 10881735Abstract: Phase change nanodroplet conjugates and methods of making and using thereof are provided. The phase change nanodroplet conjugates include a nanodroplet having a gaseous precursor on the interior and an outer shell such as a lipid monolayer, a lipid bilayer, or a polymer layer. The phase change nanodroplet conjugates can have one or more nanoparticles attached to the outer layer, e.g. via a linker. The nanoparticles can include therapeutic, prophylactic, or diagnostic nanoparticles. The phase change nanodroplet conjugates can be used for the targeted delivery of a therapeutic, prophylactic, or diagnostic nanoparticle to a target region in a subject in need thereof. The methods can include applying an effective amount of ultrasound radiation to the target region to stimulate vaporization of the gaseous precursor followed by cavitation of the resultant bubble conjugate and release or dispersing of drug or drugs inside the liposomes. Methods of making phase change nanodroplet conjugates are also provided.Type: GrantFiled: November 18, 2016Date of Patent: January 5, 2021Assignee: Arizona Board of Regents on behalf of the University of ArizonaInventors: Theodore Trouard, Terry Matsunaga, Marek Romanowski
-
Patent number: 10883104Abstract: Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.Type: GrantFiled: February 7, 2018Date of Patent: January 5, 2021Assignee: Ionis Pharmaceuticals, Inc.Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Mark J. Graham
-
Patent number: 10874683Abstract: This disclosure relates to certain N4-hydroxycytidine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of a Zika virus infection.Type: GrantFiled: March 10, 2017Date of Patent: December 29, 2020Assignee: Emory UniversityInventors: George R. Painter, David B. Guthrie, Gregory R. Bluemling, Michael R. Natchus
-
Patent number: 10874130Abstract: Steviol glycoside solutions, and methods of making steviol glycoside solutions, are described. The steviol glycoside solutions are clear and stable, and have clear solution stability, for extended periods of time.Type: GrantFiled: August 18, 2016Date of Patent: December 29, 2020Assignee: PURE CIRCLE USA Inc.Inventors: Grace Kim, Marquita L. Johnson, Avetik Markosyan, John Martin, Kian Pin Tan
-
Patent number: 10874725Abstract: A treatment of Alzheimer's disease and other disorders involving protein misfolding or aggregation is provided by enhancing or sustaining an antibody response against predominantly directed against pathological protein aggregates or neo-epitopes present on pathogenic forms of said protein or protein complex. Furthermore, therapeutic methods are described, wherein ex vivo stimulated antigen-selected peripheral blood lymphocytes are regrafted into the cognate donor.Type: GrantFiled: December 18, 2017Date of Patent: December 29, 2020Assignee: New York UniversityInventors: Karsten Henco, Roger Nitsch, Jan Grimm, Anja Zeller, Marcel Maier
-
Patent number: 10874733Abstract: The present invention relates to an immunity enhancing composition including an immune response modulator having a novel structure and, more specifically, to an immunity enhancing composition and a use of the same, wherein the immunity enhancing composition includes a lipopolysaccharide (LPS) analogue with reduced toxicity, and a cationic liposome. The present invention overcomes the physicochemical instability of a liposome, is advantageous in terms of production, transportation, and storage, and improves stability, thus being beneficial as an immune delivery system. In addition, the present invention includes an immune response modulator, and a cationic liposome, and thus exhibits an enhanced immunity-improving effect compared to the case in which an immune response modulator is used alone.Type: GrantFiled: October 30, 2017Date of Patent: December 29, 2020Assignee: EYEGENE INC.Inventors: Yang Je Cho, Kwangsung Kim, Na Gyong Lee, Shin Ae Park
-
Patent number: 10875841Abstract: Small molecule stimulators of steroid receptor coactivator-3 (SRC-3) and methods of their use as cardioprotective agents are provided. The small molecule stimulators are useful for promoting cardiac protection and repair and vascular regeneration after myocardial infarction. The compounds are also useful in preventing cardiac hypertrophy and collagen deposition and improving cardiac post-infarction function.Type: GrantFiled: August 29, 2019Date of Patent: December 29, 2020Assignee: BAYLOR COLLEGE OF MEDICINEInventors: Bert W. O'Malley, David Michael Lonard, Yongcheng Song
-
Patent number: 10872313Abstract: A method for adjudicating reimbursement for venom derived allergens between a pharmacist and a reimbursing entity comprises obtaining National Drug Codes (NDC's) for a plurality of venom derived allergens, storing in a central control database the obtained NDC's in association with an associated AWP and associated information for the venom derived allergen, which associated information includes translation information to allow practitioners to determine from a desired diluted level and number of doses of a desired NDC carrying venom derived antigen and a known dilution procedure how to translate back to the amount of base concentration of the NDC carrying venom derived antigen used to create the desired diluted level and number of doses, and determining if any of the NDC's in the central control database are contained within the third-party database and, if not, transferring the associated NDC's not in the third-party database to the third-party database.Type: GrantFiled: August 11, 2016Date of Patent: December 22, 2020Assignee: ROCA MEDICAL LTD.Inventors: James Strader, Jovan Hutton Pulitzer
-
Patent number: 10864168Abstract: Provided are lipid membrane microcapsules encapsulating or containing bioactives, and methods of production and use.Type: GrantFiled: October 28, 2015Date of Patent: December 15, 2020Assignee: The Regents of the University of CaliforniaInventors: Nitin Nitin, Stephen Young, Jean Vandergheynst
-
Patent number: 10864280Abstract: Disclosed herein are nanodroplet compositions composed of a copolymer with a hydrophilic block and a hydrophobic block, a poloxamer, an oil, an antiĀ¬cancer agent, and optionally a lyoprotectant. The nanodroplet compositions exhibit low toxicity and are biodegradable, provide for slow, sustained release of the anti-cancer agent at tumor sites, and result in a greater reduction of tumor volume when administered to subjects with cancer as compared to several commercially-available products. Furthermore, the nanodroplet compositions can be imaged and their progress through the body tracked with magnetic resonance spectroscopy or ultrasound.Type: GrantFiled: June 9, 2017Date of Patent: December 15, 2020Inventor: Der-Yang Tien
-
Patent number: 10858425Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.Type: GrantFiled: August 31, 2018Date of Patent: December 8, 2020Assignee: Eli Lilly and CompanyInventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Beth Ann Strifler, Derrick Ryan Witcher
-
Patent number: 10858305Abstract: NEO218 (3-bromo-2-oxo-propionic acid 4-isopropenyl-cyclohex-1-enylmethyl ester), (see formula 1), is a novel molecule that was generated by covalent fusion of two unrelated agents: 3-bromopyruvate (3-BF; an alkylating agent that Inhibits cancer cell metabolism) and perillyi alcohol (POH; a natural monoterpene with anticancer properties). Methods of synthesizing NBO218, pharmaceutical compositions comprising NBO218 and methods of treating cancer using NBO218 are also disclosed.Type: GrantFiled: November 29, 2017Date of Patent: December 8, 2020Assignee: NeOnc Technologies, Inc.Inventor: Thomas Chen
-
Patent number: 10845361Abstract: Disclosed herein is a formulation for detecting a species indicative of a disease in a patient. The formulation comprises a mercury-containing reagent which, when contacted with a fluid sample from the patient, colourimetrically indicates whether the fluid sample contains the species. The mercury-containing reagent is contained within a non-flowing carrier which, upon exposure to the fluid sample, causes rapid mixing of substantially all of the mercury-containing reagent and the fluid sample.Type: GrantFiled: February 5, 2016Date of Patent: November 24, 2020Assignee: ATH (AUSTRALIA) PTY LTDInventors: Allan J Chisholm, Nicolas De Luca
-
Patent number: 10844365Abstract: Systems and methods generally useful in medicine, cellular biology, nanotechnology, and cell culturing are discussed. In particular, at least in some embodiments, systems and methods for magnetic guidance and patterning of cells and materials are discussed. Some specific applications of these systems and methods may include levitated culturing of cells away from a surface, making and manipulating patterns of levitated cells, and patterning culturing of cells on a surface. Specifically, a method of culturing cells is presented. The method may comprise providing a plurality of cells, providing a magnetic field, and levitating at least some of the plurality of cells in the magnetic field, wherein the plurality of cells comprise magnetic nanoparticles. The method may also comprise maintaining the levitation for a time sufficient to permit cell growth to form an assembly.Type: GrantFiled: March 5, 2018Date of Patent: November 24, 2020Assignees: William Marsh Rice University, The Board of Regents of the University of Texas SystemInventors: Glauco R. Souza, Renata Pasqualini, Wadih Arap, Thomas Charles Killian, Robert M. Raphael, Daniel Joshua Stark
-
Patent number: 10844002Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein RA, RB, R2 and R4 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.Type: GrantFiled: September 19, 2018Date of Patent: November 24, 2020Assignee: Novartis AGInventors: Rohan Eric John Beckwith, Luis Brito, Brian Addison DeChristopher, Gabriel Grant Gamber, Andrew Geall, Thomas Zabawa
-
Patent number: 10842749Abstract: The present disclosure is directed to a composition for the sustained-release delivery of an active agent to a target cell of an individual. The compositions disclosed herein comprise of at least one porous particle; at least one polymer; and at least one active agent. In an embodiment, the porous particle comprises a plurality of microscale reservoirs. In an exemplary embodiment, the at least one active agent is covalently linked to the at least one polymer to form a polymer-active agent conjugate, and the polymer-active agent conjugate is contained in the plurality of microscale reservoirs of the porous particle. The present disclosure is also directed to a method of treating a tumor, comprising the step of administering to an individual the composition described supra. Additionally, disclosed herein is a method of eliminating tumor stem cells. Furthermore, there is provided a method of circumventing multi-drug resistance in a tumor cell.Type: GrantFiled: June 12, 2013Date of Patent: November 24, 2020Assignee: The Methodist Hospital Research InstituteInventors: Haifa Shen, Mauro Ferrari, Xiaoyong Deng, Guodong Zhang
-
Patent number: 10835494Abstract: The invention refers to a product made of liposomes which comprises lactoferrin and a component selected from hyaluronic acid or chitosan, as active ingredients, as well as to compositions comprising it and their use in the prevention and/or treatment of diseases related to the eye, such as for example the ocular diseases characterized by the presence of an inflammatory condition.Type: GrantFiled: July 31, 2019Date of Patent: November 17, 2020Assignee: TDC Technology Dedicated to Care srlInventors: Ana Laura LĆ³pez Machado, Elena SĆ”nchez LĆ³pez, Maria Luisa Garcia Lopez, Martina Biancardi
-
Patent number: 10835610Abstract: Disclosed is a pharmaceutical or cosmetic composition or medical device for topical use including: a) a cosmetically or pharmaceutically active substance; b) a polyvinylcaprolactam/polyvinyl acetate/polyethylene glycol copolymer; and c) a phospholipid. Also disclosed is a method for treatment incorporating such a composition.Type: GrantFiled: February 21, 2017Date of Patent: November 17, 2020Assignee: EMENEM S.R.L.Inventors: Celestino Ronchi, Federica Ronchi
-
Patent number: 10835583Abstract: The present invention provides, among other things, methods of treating ornithine transcarbamylase (OTC) deficiency, including administering to a subject in need of treatment a composition comprising an mRNA encoding an ornithine transcarbamylase (OTC) protein at an effective dose and an administration interval such that at least one symptom or feature of the OTC deficiency is reduced in intensity, severity, or frequency or has delayed onset. In some embodiments, the mRNA is encapsulated in a liposome comprising one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more PEG-modified lipids.Type: GrantFiled: June 13, 2017Date of Patent: November 17, 2020Assignee: Translate Bio, Inc.Inventors: Frank DeRosa, Michael Heartlein, Lianne Smith, Shrirang Karve
-
Patent number: 10828312Abstract: In one aspect, the disclosure relates to compositions of lithium cholesterol compositions, including but not limited to lithium cholesterol sulfate compositions which are useful as therapeutic agents. The disclosure also relates to methods of making lithium cholesterol compositions and pharmaceutical compositions comprising therapeutically effective amounts of the lithium cholesterol compositions. The present disclosure also includes methods of treating one or more clinical neurological conditions with the lithium cholesterol compositions, such as Alzheimer's disease, autism spectrum disorder, bipolar disorder, or other neuropsychiatric disorders.Type: GrantFiled: June 5, 2019Date of Patent: November 10, 2020Inventors: Jun Tan, Roland Douglas Shytle, Jinhua Wen, Darrell Sawmiller
-
Patent number: 10829739Abstract: The invention relates to progenitor cells of mesodermal lineage and their use in therapy.Type: GrantFiled: October 8, 2019Date of Patent: November 10, 2020Assignee: CELL THERAPY LIMITEDInventors: Thomas Averell Houze, Martin John Evans, Ajan Trevor Reginald, Ina Laura Pieper
-
Patent number: 10829546Abstract: This disclosure relates to an antibody that can protect against ETEC infection in a passive immunization set up. More specifically, it relates to a VHH grafted on an IgA scaffold and produced in plant seeds. When the seeds are given in food or feed, the subject is protected against ETEC infection.Type: GrantFiled: September 3, 2013Date of Patent: November 10, 2020Assignees: VIB VZW, Universiteit Gent, Vrije Universiteit BrusselInventors: Anna Depicker, Henri De Greve, Vikram Virdi
-
Patent number: 10828351Abstract: A liposomal vaccine composition comprises a ?-amyloid (A?)-derived peptide antigen displayed on the surface of the liposome. The vaccine composition also comprises a peptide comprising a universal T-cell epitope encapsulated within the liposome. The vaccine composition also comprises an adjuvant, which may form part of the liposome and may be displayed at least in part on the surface of the liposome. These vaccine compositions are used for treating, preventing, inducing a protective immune response against or alleviating the symptoms associated with an amyloid-beta associated disease or condition or a condition characterised by, or associated with, loss of cognitive memory capacity in a subject. The vaccine compositions may be provided as a kit. Related methods of producing a liposomal vaccine composition are also provided.Type: GrantFiled: April 9, 2019Date of Patent: November 10, 2020Assignee: AC Immune SAInventors: Emma Fiorini, Marija Vukicevic Verhille, Maria Pihlgren Bosch
-
Patent number: 10822368Abstract: Disclosed are messenger RNA molecules and related compositions incorporating a 4?-thio modification in the furanose ring of at least one nucleotide residue, and methods of using these mRNAs to produce an encoded therapeutic protein in vivo and to treat or prevent diseases or disorders. In certain embodiments, the 4?-thio modified mRNA provides for enhanced stability and/or reduced immunogenicity in in vivo therapies.Type: GrantFiled: February 21, 2019Date of Patent: November 3, 2020Assignee: Translate Bio, Inc.Inventors: Frank DeRosa, Michael Heartlein
-
Disintegratable core/shell silica particles for encapsulating and releasing bioactive macromolecules
Patent number: 10821082Abstract: The present invention relates to disintegratable core/shell silica particles encapsulating a bioactive macromolecule or bioactive macromolecule cluster in an active conformation, a method for producing the same, and uses thereof.Type: GrantFiled: June 12, 2015Date of Patent: November 3, 2020Assignee: UNIVERSITE DE STRASBOURGInventors: Luisa De Cola, Eko Adi Prasetyanto, Alessandro Bertucci, Dedy Septiadi -
Patent number: 10806779Abstract: Described are methods for preparing virosomes comprising the steps of: (a) providing an enveloped virus, and optionally inactivating the virus; (b) solubilizing the viral envelopes in a first solubilizing agent; (c) pre-solubilizing exogenous components in a second solubilizing agent; (d) adding the pre-solubilized exogenous components to the solubilized viral envelopes; and (e) reconstituting virosomal membranes by removing the solubilizing agent. According to the disclosure, the viral envelopes and the exogenous components are (pre-)solubilized at a temperature below 33Ā° C.Type: GrantFiled: June 30, 2014Date of Patent: October 20, 2020Assignee: JANSSEN VACCINES & PREVENTION B.V.Inventors: Wenyu Dong, Pieter Rijken, Mike Ugwoke
-
Patent number: 10808247Abstract: In one aspect, the disclosure provides methods for treating a neurodegenerative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule and a therapeutically effective amount of a small molecule that activates NF-?B p65 and increases expression of manganese superoxide dismutase (MnSOD/SOD2) and/or expression of a related protein or enzyme.Type: GrantFiled: July 6, 2016Date of Patent: October 20, 2020Assignees: Phio Pharmaceuticals Corp., Synaerion TherapeuticsInventors: Michael Byrne, Antonella Favit-VanPelt
-
Patent number: 10806383Abstract: A sensor is provided for measuring a dissolved oxygen concentration in vivo when implanted at a tissue site and in ex vivo applications. The sensor includes an article comprising a sensing medium retained within the implantable article by an oxygen-permeable material. The sensing medium comprises an MR contrast agent for oxygen. The sensor is configured to indicate the dissolved oxygen concentration of a fluid, e.g., in vivo at the tissue site, when subjected to an MR-based method.Type: GrantFiled: May 4, 2011Date of Patent: October 20, 2020Assignee: Massachusetts Institute of TechnologyInventors: Vincent Hok Liu, Christophoros Christou Vassiliou, Yibo Ling, Michael J. Cima
-
Patent number: 10806793Abstract: Described herein are compositions and methods useful for allowing for the absorption (passage) of agents of interest, such as therapeutic agents, across epithelial and mucosal barriers and/or into certain subcellular compartments of the cell, such as the recycling endosome (RE), Golgi, and the endoplasmic reticulum (ER).Type: GrantFiled: November 20, 2017Date of Patent: October 20, 2020Assignee: Children's Medical Center CorporationInventors: Wayne I. Lencer, Daniel J F Chinnapen, Randy Mrsny
-
Patent number: 10799561Abstract: A pharmaceutical composition for treatment of persons afflicted of heart failure with preserved ejection fraction (HFPEF), diastolic heart failure (DHF) or diastolic dysfunction (DF), the composition comprising a therapeutically effective amount of a compound capable of specific binding to the relaxin receptor (RXFP1) present on fibroblasts, fibromyoblasts, endothelial cells, endocardial cells, and cardiomyocytes in the cardiac muscle to increase the heart's stroke volume at lower end-diastolic pressure.Type: GrantFiled: January 28, 2019Date of Patent: October 13, 2020Assignee: Relaxera Pharmazeutische Gesellschaft mbH & Co. KGInventor: Thomas B. Dschietzig
-
Patent number: 10792251Abstract: Liposomes termed as small unilamellar vesicles (SUVs), can be synthesized in the 20-50 nm size range, but encounter challenges such as instability and aggregation leading to inter-particle fusion. This limits their use as a therapeutic delivery agent. Increasing the surface negative charge of SUVs, via the attachment of anionic entities such as DNA/RNA, increases the colloidal stability of these vesicles. Additionally, the dense spherical arrangement and radial orientation of nucleic acids exhibits unique chemical and biological properties, unlike their linear counterparts. These liposomal particles, are non-toxic and though anionic, can efficiently enter cells without the aid of ancillary cationic transfection agents in a non-immunogenic fashion. These exceptional properties allow their use as delivery agents for gene regulation in different therapies and offer an alternative platform to metal core spherical nucleic acids.Type: GrantFiled: January 8, 2019Date of Patent: October 6, 2020Assignees: NORTHWESTERN UNIVERSITY, EXICURE, INC.Inventors: Chad A. Mirkin, Sonbinh T. Nguyen, Resham Singh Banga, Natalia Chernyak, Sergei Gryaznov, Aleksandar Radovic-Moreno, Christopher Mader
-
Patent number: 10792328Abstract: A nanocomplex, of particle size 50 nm to 1000 nm, containing saporin and a lipid-like compound, in which saporin binds to the lipid-like compound via non-covalent interaction or covalent bonding. The lipid-like compound has a hydrophilic moiety, a hydrophobic moiety, and a linker joining the hydrophilic moiety and the hydrophobic moiety. The hydrophilic moiety is optionally charged and the hydrophobic moiety has 8 to 24 carbon atoms. Also disclosed is a pharmaceutical composition containing such a nanocomplex and a pharmaceutically acceptable carrier. The nanocomplex is useful in treating diseases, such as cancer.Type: GrantFiled: January 15, 2019Date of Patent: October 6, 2020Assignee: Trustees of Tufts CollegeInventors: Qiaobing Xu, Ming Wang
-
Patent number: 10787413Abstract: A series of novel bis(hydroxymethyl) alkanoate derivatives of curcuminoids were designed, and synthesized, which show anticancer activity, and in particular to breast cancer, colon cancer, and prostate cancer.Type: GrantFiled: June 2, 2017Date of Patent: September 29, 2020Assignee: CHINA MEDICAL UNIVERSITYInventors: Sheng-Chu Kuo, Kuo-Hsiung Lee, Chang-Hai Tsai, Min-Tsang Hsieh, Ling-Chu Chang, Hsin-Yi Hung, Hui-Yi Lin, Jai-Sing Yang
-
Patent number: 10781431Abstract: Non-naturally occurring peptides are provided that act as a Src SH2 domain antagonist of cardiotonic steroids. Pharmaceutical compositions comprising the peptides are also provided along with vectors encoding the peptides. Methods of treating a Src-associated disease and reducing Src activity in a cell are further provided and include administering or contacting a cell with an effective amount of the peptide.Type: GrantFiled: April 2, 2015Date of Patent: September 22, 2020Assignee: MARSHALL UNIVERSITY RESEARCH CORPORATIONInventors: Zijian Xie, Moumita Banerjee
-
Patent number: 10780184Abstract: The present invention discloses a solid lipid nanoparticle (SLN) comprising: a) a solid lipid core comprising at least a glyceride and/or at least a fatty acid; b) a mixture of amphiphilic components forming a shell around said core a); c) an alkaline-earth complex with a compound of formula I and/or II: d) at least a fluorescent dye selected from: a cyanine fluorescent dye and/or a polyetherocyclic compound selected from: coumarin, pyrano, quinoline, pyranoquinoline, indole and pyranoindole derivates in acid form or a pharmaceutically acceptable salt thereof. These nanoparticles allow a prolonged blood circulation half-life, show enhanced photostability and improved fluorescence signal. The dye is preserved from degradation and improves the fluorescent quantum yield.Type: GrantFiled: January 31, 2019Date of Patent: September 22, 2020Assignee: BRACCO IMAGING S.P.A.Inventors: Simona Ghiani, Alessandro Maiocchi, Lara Caminiti, Luigi Miragoli
-
Patent number: 10775393Abstract: Disclosed is a reagent for prothrombin time measurement, wherein the reagent contains a liposome composition containing a first liposome having a phospholipid layer, a second liposome having a phospholipid layer of a different composition from that of the first liposome, and tissue factor, wherein the tissue factor is associated with the phospholipid layer of at least one of the first liposome and the second liposome; the first liposome contains a phosphatidylcholine compound, a phosphatidylethanolamine compound, and a phosphatidylserine compound; and the second liposome contains at least one phospholipid selected from the group consisting of a phosphatidylcholine compound and a phosphatidylethanolamine compound.Type: GrantFiled: March 24, 2017Date of Patent: September 15, 2020Assignee: SYSMEX CORPORATIONInventors: Yusuke Tanaka, Takahiko Bando, Kiyoko Kohama, Haruki Yamaguchi
-
Patent number: 10772862Abstract: Methods and compositions for treating Ras-related cancers are provided that involve targeting lipid scavenging. Methods and compositions for identifying and/or characterizing more or less responsive cancers are also provided.Type: GrantFiled: October 15, 2018Date of Patent: September 15, 2020Assignees: The Trustees of Princeton University, Memorial Sloan Kettering Cancer CenterInventors: Joshua Rabinowitz, Jurre Kamphorst, Craig Thompson, Justin Cross
-
Patent number: 10772834Abstract: Provided are a liposome composition in which an osmotic pressure of an inner water phase is 2-fold to 8-fold relative to the osmotic pressure of an outer water phase, and which encapsulates a water-soluble drug in a dissolved state, and also exhibits excellent preservation stability; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes obtained from lipids dissolved and emulsified in an organic solvent, each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which each of the liposomes encapsulates a water-soluble drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase; and a method for producing the same.Type: GrantFiled: March 30, 2017Date of Patent: September 15, 2020Assignee: FUJIFILM CorporationInventors: Makoto Ono, Kohei Ono, Takeshi Matsumoto, Mikinaga Mori
-
Patent number: 10765636Abstract: A nanocarrier including a silica body having a surface and defining a plurality of pores that are suitable to receive molecules therein is described. The nanocarrier also includes a lipid bilayer coating the surface, and a cargo-trapping agent within the phospholipid bilayer. The phospholipid bilayer stably seals the plurality of pores. The cargo-trapping reagent can be selected to interact with a desired cargo, such as a drug.Type: GrantFiled: October 18, 2018Date of Patent: September 8, 2020Assignee: The Regents of the University of CaliforniaInventors: Andre E. Nel, Huan Meng, Xiangsheng Liu
-
Patent number: 10765633Abstract: A formulation comprising liposomes, wherein the liposomes comprise, based on the liposome, 0.7 to 3.0 mol % of eritoran or a pharmaceutically acceptable salt thereof and 0.5 to 3.0 mol % of a PEGylated phospholipid.Type: GrantFiled: December 13, 2019Date of Patent: September 8, 2020Assignee: EISAI R&D MANAGEMENT CO., LTDInventors: Hiroshi Ishihara, Katsura Hata, Hiroki Muto, Geoff Hird
-
Patent number: 10765654Abstract: The invention includes, in part, methods and compounds for treating cancer including, but not limited to gliomas, melanomas, and neuroblastomas. In some embodiments of the invention, a glyceryltriacetate compound is administered to a subject in an amount effective to treat or prevent a cancer in the subject.Type: GrantFiled: July 19, 2012Date of Patent: September 8, 2020Assignee: University of Vermont and State Agricultural CollegeInventor: Diane M. Jaworski
-
Patent number: 10751306Abstract: Methods for treating or preventing liver fibrosis in a subject by administering to the subject a therapeutically effective amount of 3-bromopyruvate (3-BrPA) are provided. In addition, methods for promoting the reversal of an activated hepatic stellate cell (HSC) to an inactivated HSC by contacting the activated HSC with at least one 3-bromopyruvate (3-BrPA) molecule are also provided.Type: GrantFiled: November 4, 2016Date of Patent: August 25, 2020Assignee: The Johns Hopkins UniversityInventors: Shanmugasundaram Ganapathy-Kanniappan, Surojit Sur, Bert Vogelstein, Kenneth W. Kinzler, Jean-Francois Geschwind
-
Patent number: 10752909Abstract: Disclosed herein are compositions for conferring oral tolerance in mammals to autoimmune disorders such as diabetes, as well as vectors and methods for plastid transformation of plants to produce a CTB-Pins protein for oral delivery. The invention also extends to the transformed plants, plant parts, and seeds and progeny thereof. The invention is applicable to plants edible without torrefying. Exemplified herein is the stable transformation of Lactuca sativa such that CTB-Pins is expressed.Type: GrantFiled: March 31, 2008Date of Patent: August 25, 2020Assignee: The Trustees of the University of PennsylvaniaInventor: Henry Daniell
-
Patent number: 10752923Abstract: The present invention generally relates to the field of biotechnology as it applies to the production of hydroxycinnamic acids using polypeptides having tyrosine ammonia lyase activity. More particularly, the present invention pertains to polypeptides having tyrosine ammonia lyase activity and high substrate specificity towards tyrosine, which makes them particularly suitable in the production of p-coumaric acid and other hydroxycinnamic acids. The present invention thus provides processes for the production of p-coumaric acid and other hydroxycinnamic acids employing these polypeptides as well as recombinant host cells expressing same.Type: GrantFiled: July 14, 2015Date of Patent: August 25, 2020Assignee: CYSBIO APSInventors: Christian Bille Jendresen, Solvej Siedler, Steen Gustav Stahlhut, Alex Toftgaard Nielsen
-
Patent number: 10751355Abstract: Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period.Type: GrantFiled: January 31, 2019Date of Patent: August 25, 2020Assignee: INSMED INCORPORATEDInventors: Gina Eagle, Renu Gupta
-
Patent number: 10744089Abstract: The invention relates to the use of empty liposomes of defined lipid composition or mixtures of empty liposomes of defined lipid composition and to the use of other lipid bilayers or monolayers of defined lipid composition for the treatment and prevention of bacterial infections. It has been found that such liposomes, in particular a two- and a four-component mixture of liposomes comprising cholesterol and sphingomyelin, liposomes consisting of sphingomyelin, liposomes comprising sphingomyelin and phosphatidylcholine, and liposomes comprising cholesterol and phosphatidylcholine efficiently sequestrate a variety of toxins secreted by bacteria, thus preventing binding of bacterial toxins to target cells and toxin-induced lysis of the target cells. Injected intravenously, liposome mixtures prevented death of laboratory mice infected with lethal doses of Staphylococcus aureus or Streptococcus pneumoniae.Type: GrantFiled: June 13, 2013Date of Patent: August 18, 2020Assignee: UNIVERSITAET BERNInventors: Eduard Babiychuk, Annette Draeger
-
Patent number: 10744151Abstract: Compositions and methods for treating a disease are described herein. Compositions having plant preparations, microRNAs, and one or more rate limiters are administered to a patient to promote DNA damage repair and modulate endothelial and mitochondrial function, thereby allowing for healing to occur.Type: GrantFiled: October 5, 2018Date of Patent: August 18, 2020Assignee: GOWEY RESEARCH GROUP PLLCInventor: Brandie Gowey